BRPI0910509A2 - composição farmacêutica, anticorpos, uso do anticorpo, polipeptídeos, polipeptídeo de cdr de cadeia pesada, polipeptídeo de cdr de cadeia leve e dna - Google Patents

composição farmacêutica, anticorpos, uso do anticorpo, polipeptídeos, polipeptídeo de cdr de cadeia pesada, polipeptídeo de cdr de cadeia leve e dna

Info

Publication number
BRPI0910509A2
BRPI0910509A2 BRPI0910509A BRPI0910509A BRPI0910509A2 BR PI0910509 A2 BRPI0910509 A2 BR PI0910509A2 BR PI0910509 A BRPI0910509 A BR PI0910509A BR PI0910509 A BRPI0910509 A BR PI0910509A BR PI0910509 A2 BRPI0910509 A2 BR PI0910509A2
Authority
BR
Brazil
Prior art keywords
chain cdr
cdr polypeptide
polypeptides
antibodies
dna
Prior art date
Application number
BRPI0910509A
Other languages
English (en)
Inventor
Fumiyoshi Okano
Masaki Shimizu
Takanori Saito
Takayoshi Ido
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BRPI0910509A2 publication Critical patent/BRPI0910509A2/pt
Publication of BRPI0910509B1 publication Critical patent/BRPI0910509B1/pt
Publication of BRPI0910509B8 publication Critical patent/BRPI0910509B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0910509A 2008-07-10 2009-07-10 uso do anticorpo, anticorpo e composição farmacêutica BRPI0910509B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008-1800572008 2008-07-10
JP2008180057 2008-07-10
JP2009-0873792009 2009-03-31
JP2009087379 2009-03-31
PCT/JP2009/062573 WO2010005068A1 (ja) 2008-07-10 2009-07-10 癌の治療及び予防用医薬組成物

Publications (3)

Publication Number Publication Date
BRPI0910509A2 true BRPI0910509A2 (pt) 2015-09-29
BRPI0910509B1 BRPI0910509B1 (pt) 2021-05-04
BRPI0910509B8 BRPI0910509B8 (pt) 2021-05-25

Family

ID=41507178

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910509A BRPI0910509B8 (pt) 2008-07-10 2009-07-10 uso do anticorpo, anticorpo e composição farmacêutica

Country Status (16)

Country Link
US (2) US10611835B2 (pt)
EP (1) EP2305300B1 (pt)
JP (1) JP5573156B2 (pt)
KR (1) KR101669834B1 (pt)
CN (1) CN102089004B (pt)
AU (1) AU2009270181B2 (pt)
BR (1) BRPI0910509B8 (pt)
CA (1) CA2730201C (pt)
DK (1) DK2305300T3 (pt)
ES (1) ES2575430T3 (pt)
HU (1) HUE028589T2 (pt)
MX (1) MX2011000117A (pt)
PL (1) PL2305300T3 (pt)
PT (1) PT2305300E (pt)
RU (1) RU2533460C2 (pt)
WO (1) WO2010005068A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6865688B2 (ja) 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
AU2016249408A1 (en) 2015-04-16 2017-11-09 H. Lundbeck A/S. Anti-PACAP antibodies and uses thereof
PL3290051T3 (pl) * 2015-04-30 2020-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
WO2017136607A1 (en) 2016-02-02 2017-08-10 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
TWI770020B (zh) 2016-04-15 2022-07-11 丹麥商Ｈ朗德貝克公司 人類化抗pacap 抗體及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2014073A (en) * 1935-09-10 Stovepipe
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO1999006541A1 (fr) * 1997-07-29 1999-02-11 Sumitomo Electric Industries, Ltd. Anticorps du recepteur des cellules pre-b non humaines
BR9909382A (pt) 1998-04-03 2000-12-05 Chugai Pharmaceutical Co Ltd Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
US6703360B2 (en) 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors
CA2469833C (en) 2001-12-21 2008-05-20 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
WO2004024750A2 (en) 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
EP2960251A1 (en) * 2003-05-09 2015-12-30 Duke University CD20-specific antibodies and methods of employing same
JPWO2005083074A1 (ja) 2004-03-01 2007-11-22 有限会社金沢大学ティ・エル・オー 腫瘍抗原ペプチド
KR100942849B1 (ko) 2004-03-30 2010-02-17 글락소 그룹 리미티드 면역글로불린
US8999633B2 (en) 2004-05-28 2015-04-07 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans
JP4547197B2 (ja) 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
JP2007053501A (ja) 2005-08-16 2007-03-01 Matsushita Electric Ind Co Ltd 管理装置、ｉｐ電話装置、ｉｐ電話システム及び更新方法
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
AU2007254853B2 (en) * 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008141197A1 (en) 2007-05-10 2008-11-20 Sea Lane Biotechnologies, Llc Chain reaction creating oligomers from repeat units of binding molecules
CA2730088C (en) * 2008-07-10 2020-04-14 Toray Industries, Inc. Immunity-inducing agent and method for detection of cancer
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
DK3342786T3 (en) * 2010-01-29 2021-09-27 Chugai Pharmaceutical Co Ltd Anti-dll3-antistof
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use

Also Published As

Publication number Publication date
AU2009270181B2 (en) 2014-05-29
PT2305300E (pt) 2016-06-16
PL2305300T3 (pl) 2016-09-30
EP2305300A1 (en) 2011-04-06
US20110129478A1 (en) 2011-06-02
EP2305300B1 (en) 2016-04-06
US20200247888A1 (en) 2020-08-06
EP2305300A4 (en) 2011-11-02
RU2011104709A (ru) 2012-08-20
CN102089004B (zh) 2018-06-01
JP5573156B2 (ja) 2014-08-20
BRPI0910509B8 (pt) 2021-05-25
CA2730201C (en) 2019-02-05
CA2730201A1 (en) 2010-01-14
KR20110039423A (ko) 2011-04-18
ES2575430T3 (es) 2016-06-28
US11993650B2 (en) 2024-05-28
US10611835B2 (en) 2020-04-07
HUE028589T2 (en) 2016-12-28
AU2009270181A1 (en) 2010-01-14
MX2011000117A (es) 2011-02-25
JPWO2010005068A1 (ja) 2012-01-05
DK2305300T3 (en) 2016-06-06
KR101669834B1 (ko) 2016-10-27
WO2010005068A1 (ja) 2010-01-14
CN102089004A (zh) 2011-06-08
BRPI0910509B1 (pt) 2021-05-04
RU2533460C2 (ru) 2014-11-20

Similar Documents

Publication Publication Date Title
HRP20190312T1 (hr) Vežući proteini, uključujući protutijela, derivate protutijela i fragmente protutijela, koji se specifično vežu na cd154 i njihova upotreba
CY2023018I1 (el) Συνθεσεις αντισωματων anti-ctla-4
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0820543A2 (pt) Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo
BRPI0924177A2 (pt) Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
BRPI0812400A2 (pt) Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
BRPI0905076A2 (pt) Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo
BRPI0918947A2 (pt) proteína de fusão de anticorpo
BRPI0821447A2 (pt) Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
SI2162467T1 (sl) Polipeptidi, protitelesne variabilne domene in antagonisti
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0715989A8 (pt) "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição"
BRPI0807480A2 (pt) Ligando, imunoglobulina g, composição e proteína de fusão
CL2014000400A1 (es) Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
IL201399A0 (en) Polypeptides, antibody variable domains and antagonists
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
BRPI0811637A2 (pt) Proteínas de fusão da imunoglobina
BRPI0807118A2 (pt) Material, uso de um material, dispositivo de emissão de luz, e, sistema.
DK2185574T3 (da) Antistoffer og relaterede molekyler, der bindes til 24P4C12-proteiner
DK2031987T3 (da) Syrnede proteindrikke, der indeholder suspenderede partikulære materialer, og fremgangsmåder til fremstilling heraf
BRPI0814127A2 (pt) Polipeptídeos imunegênicos e anticorpos monoclonais
DK2171060T3 (da) Superagonistisk anti-CD28-antistof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF